CG Oncology (CGON) Accounts Payables (2023 - 2026)
CG Oncology's (CGON) quarterly Accounts Payables came in at $8.2 million in Q1 2026, up 22.36% YoY from $6.7 million in Q1 2025, and up 44.14% on a QoQ basis from $5.7 million in Q4 2025.
CG Oncology (CGON) Accounts Payables (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Accounts Payables data on file, last reported at $8.2 million in Q1 2026.
- Quarterly Accounts Payables rose 22.36% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 22.36% YoY) and the FY2025 annual result came in at $5.7 million, down 12.32% from the prior year.
- Accounts Payables improved to $8.2 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $9.2 million in Q3 2025 to a low of $3.2 million in Q4 2023.
- A 4-year average of $6.0 million and a median of $6.1 million in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 125.54% in 2025, down 12.32% in 2025.
- Tracing CGON's Accounts Payables over 4 years: stood at $3.2 million in 2023, then jumped by 101.02% to $6.5 million in 2024, then fell by 12.32% to $5.7 million in 2025, then jumped by 44.14% to $8.2 million in 2026.
- The last three Accounts Payables figures came in at $8.2 million (Q1 2026), $5.7 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.73 Mn |
| Mar 31, 2026 | 8.24 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 9.19 Mn |
| Jun 30, 2025 | 7.13 Mn |
| Mar 31, 2025 | 6.73 Mn |
| Dec 31, 2024 | 6.52 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 3.24 Mn |